BriaCell Therapeutics ( (TSE:BCT) ) has shared an update.
BriaPro Therapeutics Corp., a subsidiary of BriaCell Therapeutics Corp., has released its unaudited financial statements for the three months ending October 31, 2024. The report highlights a comprehensive loss for the period, with a noted increase in liabilities compared to previous figures, potentially impacting the company’s financial stability and stakeholder confidence.
More about BriaCell Therapeutics
BriaCell Therapeutics Corp. operates in the biotechnology industry, focusing on developing treatments for cancer. Its subsidiary, BriaPro Therapeutics Corp., forms a significant part of its operations.
YTD Price Performance: -87.82%
Average Trading Volume: 75,348
Technical Sentiment Consensus Rating: Buy
Current Market Cap: C$34.37M
See more insights into BCT stock on TipRanks’ Stock Analysis page.